Article
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Basic & clinical pharmacology & toxicology - 1 Feb 2009
Gréen Henrik, Söderkvist Peter, Rosenberg Per, Mirghani Rajaa A, Rymark Per, Lundqvist Elisabeth Avall, Peterson Curt
Abstract excerpt
The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients. Thirty-eight patients were treated with paclitaxel and carboplatin. The genotypes of CYP2C8*1B, *1C, *2, *3, *4, *5, *6, *7, *8 and P404A, ABCB1 G2677T/A and C3435T, as well as CYP3A4*1B, were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.